3i divests Ambea to Triton
Mannheimer Swartling has advised 3i on the divestment of Nordic healthcare group Ambea to Triton for approximately EUR 850 million on a cash and debt free basis.
3i is an international leader in private equity focusing on buyouts, growth capital and infrastructure and invest across Europe, Asia and North America. Ambea is the leading provider of healthcare and care services in the Nordic region and one of the largest European healthcare service providers. The group operates under the Carema brand in Sweden and Norway and under the Mehiläinen brand in Finland. The transaction is conditioned on EU competition clearance.
Mannheimer Swartling’s team handling the transaction included Jan Holmius, Tom Wehtje, Andreas Elving, Henrik Johansson, Jona Lundborg, Siri Öhman and Elise Avsan (M&A), Eva Hägg, Nina Svensson and Nils Nostell (Capital Markets), Stefan Perván Lindeborg and Urszula Sieradzka (EU Competition Law), Anders Erasmie and Fredrik Berndt (Tax), Daniel Karlsson and Veronica Stiller (Banking and Finance).